The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.

Meanwhile, Tango tries again in PRMT5.

Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.

Imbruvica faces challenges on multiple fronts.

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.

Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.

The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.